1. Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
- Author
-
Mayuko Kawabe, Takafumi Kuroda, Izumi Yamamoto, Akimitsu Kobayashi, Yutaro Ohki, Ayaka Hayashi, Fumihiko Urabe, Jun Miki, Hiroki Yamada, Takahiro Kimura, Nanae Matsuo, Yudo Tanno, Tetsuya Horino, Ichiro Ohkido, Hiroyasu Yamamoto, and Takashi Yokoo
- Subjects
Medicine ,Science - Abstract
Abstract The humoral response of kidney transplant recipients (KTR) to the mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is generally poor. We evaluated the booster effect of the third dose (D3) of two SARS-CoV-2 mRNA vaccines 6 months after the second dose (D2) in Japanese KTR. The anti-spike (anti-S) antibody titer 1 and 3 months after the D3 was evaluated in 82 Japanese KTR. The primary endpoint was the seropositivity rate, and factors associated with the lack of a response were evaluated in a logistic regression model. Overall, the anti-S antibody seropositivity rate 1 and 3 months after the D3 was 74.7% and 76.0%. The anti-S antibody titers after the first and second doses were higher in patients vaccinated with the mRNA-1273 than with the BNT162b2 vaccine. Among the 38 KTR who were seronegative 5 months after the D2, 18 (47.4%) became seropositive following the D3. Factors associated with a non-response were mycophenolic acid dose, post-transplant duration, hemoglobin, and lymphocyte count. A humoral response 1 and 3 months after the D3 was obtained in ~ 75% of KTR, but 20% were non-responders. Additional studies are needed to clarify the factors hindering a vaccine response.
- Published
- 2023
- Full Text
- View/download PDF